Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17577384 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX2NR1H2 | |
| SCHEMBL27219245 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL15212838 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL20813371 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL3669650 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL19214900 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL15212714 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL29369805 | 0.81 | CHRM2 (0.40) | CHRM2CHRM1CHRM3EPHX2NR1H2 | |
| SCHEMBL7035680 | 0.78 | CHRM2 (0.42) | CHRM2CHRM1CHRM3EPHX2HSD11B1 | |
| SCHEMBL21274860 | 0.76 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CHRM2 4861/4885CHRM1 4876/4885CHRM3 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.